|6 Months Ended|
Jun. 30, 2019
|Notes to Financial Statements|
|NOTE N – SUBSEQUENT EVENTS||
 On July 14, 2019, 125,000 restricted stock units owned by the Company's Chairman and Chief Executive Officer vested in accordance with his employment agreement dated July, 14, 2016 (see Note H hereof). With respect to the vesting of such restricted stock units, the Company's Chairman and Chief Executive Officer delivered 56,813 shares of common stock to satisfy withholding taxes and received 68,187 net shares of common stock.
 On July 25, 2019, the Board of Directors of the Company declared a cash dividend of $.05 per common share with a payment date of September 20, 2019 to all common stockholders as of September 4, 2019.
 On August 9, 2019, ILiAD notified the Company that the FDA has allowed Phase 2b to proceed to full enrollment based on satisfactory safety data from the first phase of the clinical study. As a result, the Company is obligated to invest an additional $1,500,000 in ILiAD for 566,038 Class C units at $2.65 per unit and receive five-year warrants to purchase 186,792 Class C units at an exercise price of $3.50 per unit (see Note J hereof).
Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef